Private: Gallery Post #1

03

May2017

PDCI Welcomes Strategic Partner John-Paul Dowson!

PDCI Market Access is delighted to announce the addition of John-Paul Dowson to the PDCI team as an external Advisor and Strategic Partner. John-Paul is Managing Director of Roubaix Strategies Inc., an advisory firm dedicated to helping organizations evaluate, develop and implement highly effective private and public market access strategies, ... Read More

02

May2017

Join PDCI at 3rd Annual Canadian Institute Pharma Symposium

Join PDCI at 3rd Annual Canadian Institute Pharma Symposium  PDCI Market Access is delighted to participate in the 3rd Annual Canadian Institute’s Pharma Symposium. The Pharma Symposium brings together leading stakeholders in pharmaceutical market access & policy to analyze the key issues facing the industry in today’s complex environment. Participants will ... Read More

19

Apr2017

New NPDUIS Report Released – PMPRB Meds Entry Watch

The new PMPRB Meds Entry Watch annual publication explores the market entry dynamics of new drugs launched in Canada and other international markets. This first edition of the report provides both a retrospective analysis of the new drugs launched over a six-year period from 2009 to 2014, and an early ... Read More

19

Apr2017

New INESSS Questionnaires Released for Medicines Under Review

The drug products being evaluated as part of the October 2017 update to the List of Medications now been made public by INESSS. Health professionals, citizens, patients, and their associations and groups may submit comments on any of the products under consideration before May 12, 2017. As part of this ... Read More

13

Apr2017

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of March 31, 2017: 30 negotiations are currently underway with 3 new files added since the last update of February 28, 2017: Votrient (pazopanib hydrochloride): Used to treat genitourinary metastatic renal cell carcinoma Campral ... Read More

28

Mar2017

CADTH’s Updated Guidelines for the Economic Evaluation of Health Technologies – 4th Edition Now Available

The updated guidelines recognize the substantial advances that have been made in the methods of economic evaluation and they offer up-to-date guidance on the best practices for determining the economic value of health technologies. Available for download at the following link.

17

Mar2017

New CADTH Processes and March Newsletter

New CADTH Processes Expanding CADTH’s Drug Review Processes to Include Radiopharmaceuticals In collaboration with the participating jurisdictions, CADTH is pleased to announce that they will accept submissions for Radiopharmaceutical Submissions and Other Process Alignment Implementations effective April 1, 2017. Applicants/Submitters planning to file a submission or resubmission for a radiopharmaceutical on ... Read More

16

Mar2017

The pan-Canadian Pharmaceutical Alliance (pCPA): Negotiations Status Update

The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of February 28, 2017: 33 negotiations are currently underway with 2 new files added since the last update of January 31, 2017: Eylea (aflibercept): Used to treat macular edema secondary to branch retinal vein ... Read More

15

Mar2017

CADTH Special Event: New Guidelines for the Economic Evaluation of Health Technologies: Canada

CADTH is hosting an online or in person event on Tuesday, March 28, 2017 to release the fourth edition of the Guidelines for the Economic Evaluation of Health Technologies: Canada. The Guidelines are intended to help produce credible and standardized economic information that is relevant and useful to decision-makers in Canada’s ... Read More

15

Mar2017

INESSS Manufacturer Appointments

INESSS Upcoming Meetings with Manufacturers – October 2017 “Liste des médicaments” INESSS is offering an opportunity for in-person meetings to manufacturers who have filed a submission by the March 24, 2017 deadline for drugs to be listed on the October 2017 “Liste des médicaments". These meetings will be held between April ... Read More